<div><div><div>Scientists at IOCB Prague have developed a breakthrough technology that streamlines aptamer development. The new method integrates several biochemical and bioinformatics steps and paves the way for new diagnostic and therapeutic applications. Ongoing applications include wearable sensors that monitor selected biomarkers in real time and provide early warnings of impending health complications. The findings were published in Nature Communications.</div></div><div>Aptamers are short DNA or RNA strands that can recognize and bind to a specific target molecule with high precision. Similar to antibodies, they can be used to detect these molecules or modulate their activity. Unlike antibodies, they are much more stable, can be produced synthetically, and can be chemically modified to achieve the desired properties. As a result, they can offer capabilities that cannot be achieved with antibodies.</div><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_2_81e99b9900.jpg" alt="IOCHB Prague: New technology streamlines the development of aptamers, synthetic alternatives to antibodies: Chemically modified DNA aptamer bound to the target protein." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_2_81e99b9900.jpg 228w," sizes="100vw" width="1343" height="916">As demand grows for accurate and rapid diagnostic tools, aptamers are often better suited to these applications than antibodies. However, developing aptamers is both experimentally demanding and time-consuming. A team of scientists from IOCB Prague, led by Dr. Marek Ondruš and <a target="_blank" rel="noopener noreferrer" href="https://hocek.group.uochb.cz/en">Prof. Michal Hocek</a>, has now developed a technology that significantly shortens the development process.“Developing an aptamer is often like looking for a needle in a haystack. Among trillions of different DNA sequences, we search for the one that binds strongly and specifically to a target molecule. Our new approach first screen for ‘aptamer families’ – hundreds of related sequences – and then identify the best-performing member of the family. This approach can reduce development time from several months to only a few days,” says Marek Ondruš.<blockquote>Video:<a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/watch?v=_3zXUeVMugU"> New technology streamlines the development of aptamers, synthetic alternatives to antibodies&nbsp;</a></blockquote>The team has also expanded the potential applications of aptamers by chemically modifying their building blocks. For example, introducing functional groups similar to those found naturally in amino acids allows the resulting molecules to combine the advantages of both DNA and antibodies: Their sequence is encoded by the order of nucleotides in DNA, while the attached chemical modifications greatly expand their ability to recognize biologically relevant targets and mimic interactions between proteins that are underlying many biological processes.The researchers demonstrated the potential of this new method using the human insulin receptor, a key protein that regulates blood sugar levels. They developed an aptamer that specifically binds to the receptor and elucidated the molecular basis of this interaction using cryo-electron microscopy. “We have shown that chemically introduced functional groups play a crucial role not only in target recognition and formation of the aptamer–protein complex, but also in stabilizing the DNA aptamer’s structure. Our findings provide new insights into how chemically modified nucleic acids can mimic key properties of proteins,” says Marek Ondruš.In the future, the technology could complement – or, in some applications, even replace – antibody-based diagnostic tools. Researchers are collaborating with <a target="_blank" rel="noopener noreferrer" href="http://iocbtech.cz/">IOCB Tech</a> on its further development, as the company helps to bring discoveries from IOCB Prague into practical applications.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_9694c21671.jpg" alt="IOCHB Prague/Tomáš Belloň: New technology streamlines the development of aptamers, synthetic alternatives to antibodies: Dr. Marek Ondruš, first author of the study, and Prof. Michal Hocek, head of the Bioorganic and Medicinal Chemistry of Nucleic Acids research group at IOCB Prague." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_9694c21671.jpg 234w," sizes="100vw" width="2000" height="1335"><blockquote><h4>Original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41467-026-73676-y#citeas">Expedient single-round selection of hyper-modified aptamer targeting insulin receptor from over-represented dually nucleobase-modified DNA libraries</a></h4>ablo Alberto Franco-Urquijo, Marek Ondruš, Jaroslav Kurfürst, Jana Škerlová, Irena Selicharová, Lucie Mužíková Čechová, Hana Šváchová, Alena Semerádtová, Anatolij Filimoněnko, Adéla Fejfarová, Jiří Homola, Tomáš Kouba &amp; Michal HocekNat. Commun., 2026<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1038/s41467-026-73676-y">https://doi.org/10.1038/s41467-026-73676-y</a>&nbsp;<h6>licenced under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>Discovery of functional nucleic acids from randomized libraries typically relies on multiple, time-consuming iterative rounds of in vitro selection with low success rate. Here, we present a single-round selection strategy for rapid screening of multiple over-represented nucleobase-modified DNA libraries and various selection conditions, capable of identifying high-affinity modified aptamers. Double partition followed by amplification of eluted sequences, NGS analysis and clustering provides fast identification of aptamer candidates. Screening of modified DNA libraries containing modified adenine and uracil nucleotides bearing hydrophobic aromatic phenyl and indole moieties results in development of an aptamer binding human insulin receptor with sub-nanomolar affinity and exquisite specificity. Cryo-EM structure reveals the importance of each aromatic modification, either in stabilizing the secondary structure or facilitating interactions with the protein surface. This approach addresses the main drawbacks of aptamer selection and has potential for high-throughput screening and accelerating the development of next-generation aptamers for diagnostics or therapeutics.</div>

New technology streamlines the development of aptamers, synthetic alternatives to antibodies

Clarity 10.2 expands instrument control capabilities with new control modules and updates the MS extension to help you work more efficiently.<h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/999">Clarity</a> 10.2 highlights</h4><ul><li>New and updated control modules</li><li>Improved MS data import and export</li><li>Obsolete hardware support ended</li></ul><h4>Instrument control modules</h4>Clarity 10.2 introduces new instrument control modules from Annuo (AS-3117, FAS-3823) and updated instrument controls form Sykam and Ecom.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Data_Apex_Instrument_control_modules_5de26782b0.jpg" alt="DataApex: Instrument control modules" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Data_Apex_Instrument_control_modules_5de26782b0.jpg 228w," sizes="100vw" width="380" height="260"><h4>MS data import/export improvements</h4>Clarity improves MS data exchange, especially for *.cdf files. MS instruments now support export and import of multiple spectral data and non-spectral signal data in the same CDF file. Import also better handles uniform sampling information, m/z Step values, scale factors, and file names with non-ASCII characters. Exporting individual chromatogram signals from MS instruments is now available through a separate Export Chromatogram dialog.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Data_Apex_MS_data_import_export_improvements_a7967a4020.jpg" alt="DataApex: MS data import-export improvements" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Data_Apex_MS_data_import_export_improvements_a7967a4020.jpg 228w," sizes="100vw" width="378" height="259"><h4>Obsolete hardware support terminated</h4>Due to changes in Windows driver security requirements, this update discontinues support for obsolete hardware, including INT7, INT9, U-PAD, U-PAD2, and CB20.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Data_Apex_Obsolete_hardware_support_terminated_24d9329419.jpg" alt="DataApex: Obsolete hardware support terminated" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Data_Apex_Obsolete_hardware_support_terminated_24d9329419.jpg 228w," sizes="100vw" width="378" height="259"><blockquote>Explore the complete list of all changes, fixes, and additions in version 10.2.👉<a target="_blank" rel="noopener noreferrer" href="https://www.dataapex.com/version_history?product=1">See the complete changelog&nbsp;</a></blockquote>

Clarity Chromatography Software 10.2 released!

🎤Dr. Leigh Terry (University of Alabama)In this episode of Concentrating on Chromatography, we sit down with Dr. Leigh Terry from the University of Alabama to explore one of the biggest challenges in environmental analysis today: understanding—and accurately measuring—PFAS in water systems.While most regulatory methods focus on a small number of compounds like PFOA and PFOS, there may be thousands of PFAS compounds in the environment—and much of that burden goes undetected.<h4>In this episode, we cover:</h4><ul><li>Why PFAS are called “forever chemicals” (and why that label is evolving)</li><li>The limitations of targeted LC-MS/MS methods</li><li>What the fluorine mass balance problem reveals about PFAS destruction</li><li>How combustion ion chromatography (CIC) helps measure total organofluorine</li><li>Why “99.99% removal” doesn’t always mean what you think</li><li>Where PFAS actually end up in wastewater treatment systems</li><li>The most effective technologies for PFAS removal today</li><li>Why drinking water may only account for ~20% of total PFAS exposure</li></ul><h4>Key Insight:</h4>Even when analyzing dozens of PFAS compounds, researchers may only be capturing a small fraction of total organic fluorine—raising major questions about how we monitor and regulate these contaminants.<h3>Video Transcription</h3>In this episode of Concentrating on Chromatography, Dr. Leigh Terry discusses PFAS contamination in drinking water, the analytical challenges associated with measuring these compounds, current treatment technologies, and future directions for monitoring and regulation. The conversation highlights how analytical chemistry, environmental engineering, and public health intersect in addressing one of today's most discussed classes of emerging contaminants.<h4>Understanding PFAS and Their Significance</h4><h5>The University of Alabama Water Quality Research Center</h5>Dr. Leigh Terry is part of the University of Alabama's Center for Water Quality Research. The center operates an analytical laboratory focused on drinking water quality and the detection of contaminants at extremely low concentrations.The laboratory specializes in:<ul><li>Drinking water analysis</li><li>Organic contaminants</li><li>Emerging contaminants</li><li>PFAS monitoring</li><li>Water quality research</li></ul>Their work supports both research initiatives and practical solutions for water utilities and environmental agencies.<h4>Why Focus on PFAS?</h4>Although PFAS compounds have existed since the 1940s, public awareness has increased dramatically only in recent years.According to Dr. Terry, several factors contributed to the rapid growth of PFAS research:<ul><li>Increased media attention</li><li>New regulatory initiatives</li><li>Growing evidence of human exposure</li><li>Expanding research opportunities</li><li>Greater understanding of potential health risks</li></ul>PFAS are not new contaminants. Rather, society is only beginning to understand their prevalence in the environment and their potential impacts on human health.<h4>The Development of Standardized PFAS Methods</h4>One major advancement in PFAS analysis has been the development of standardized EPA methods.These methods allow:<ul><li>Consistent testing procedures</li><li>Comparable results between laboratories</li><li>Regulatory monitoring</li><li>Reliable data interpretation</li></ul>Dr. Terry notes that many of these standardized approaches began appearing around 2018–2019, providing a common framework for analytical laboratories and researchers.<h4>How Large Is the PFAS Universe?</h4>Many people are familiar with PFOA and PFOS, two of the most heavily studied PFAS compounds. However, these represent only a small fraction of the broader PFAS family.PFOA and PFOS are often referred to as:<ul><li>Legacy PFAS compounds</li><li>Original PFAS contaminants</li><li>Early commercial PFAS chemicals</li></ul>The challenge is that even minor modifications to molecular structure create entirely new PFAS compounds.Researchers estimate:<ul><li>Thousands of PFAS compounds exist</li><li>Some estimates exceed 10,000 compounds</li><li>Exact numbers depend on how PFAS are defined</li></ul>Scientific debate continues regarding classification and definition, making precise counting difficult.<h4>Why PFAS Are Called "Forever Chemicals"</h4>Dr. Terry notes that the phrase "forever chemicals" has become widely used, although she suggests the terminology could benefit from rebranding.PFAS persistence results from two key chemical properties.<h5>1. Amphiphilic Structure</h5>PFAS molecules contain:<ul><li>A water-loving (hydrophilic) head group</li><li>A water-repelling (hydrophobic) fluorinated tail</li></ul>This unusual combination allows PFAS to partition between:<ul><li>Water</li><li>Solids</li><li>Air-water interfaces</li><li>Foam</li></ul>Unlike many organic compounds, PFAS can interact effectively with multiple environmental phases.<h5>2. Extremely Strong Carbon–Fluorine Bonds</h5>The carbon–fluorine bond is among the strongest bonds in organic chemistry.As Dr. Terry explains:<ul><li>Large amounts of energy are required to break these bonds</li><li>Natural degradation processes are often ineffective</li><li>Destruction can require highly aggressive treatment conditions</li></ul>These properties make PFAS extremely persistent in both environmental systems and biological organisms.<h4>Toxicity, Regulations, and Environmental Behavior</h4><h5>Understanding PFAS Toxicity</h5>One of the biggest challenges in PFAS regulation is the incomplete understanding of toxicity.Dr. Terry explains that EPA regulations generally consider three factors:<ul><li>Presence in drinking water sources</li><li>Toxicity to humans</li><li>Availability of practical treatment options</li></ul>While some PFAS compounds are known to be harmful, many others remain insufficiently studied. Furthermore, PFAS often occur as mixtures rather than individual compounds.This creates important scientific questions:<ul><li>What is the toxicity of individual PFAS?</li><li>What is the toxicity of PFAS mixtures?</li><li>How should cumulative exposure be evaluated?</li></ul>These uncertainties continue to drive active research.<h4>What Happens to PFAS in Wastewater Treatment Plants?</h4>PFAS do not behave like many conventional contaminants.Rather than remaining fully dissolved in water, they often accumulate at interfaces such as:<ul><li>Water-solid interfaces</li><li>Water-air interfaces</li><li>Foam layers</li><li>Biological solids</li></ul>As a result:<ul><li>Some PFAS accumulate in biosolids</li><li>Some partition into foam</li><li>Some remain in treated effluent</li></ul>Their distribution depends on wastewater composition and treatment processes.<h4>Regulatory Monitoring and Targeted LC-MS Analysis</h4>Current EPA regulations focus on targeted analysis of specific PFAS compounds.Examples include:<ul><li>PFOA</li><li>PFOS</li></ul>Drinking water regulations currently establish maximum contaminant levels (MCLs) for these compounds at extremely low concentrations.Advantages of targeted LC-MS analysis include:<ul><li>Clearly defined analytes</li><li>Established regulatory limits</li><li>High analytical sensitivity</li><li>Reliable quantitation</li></ul>However, limitations remain:<ul><li>Only a small subset of PFAS is measured</li><li>Many PFAS compounds remain undetected</li><li>Total PFAS burden may be underestimated</li></ul>As Dr. Terry notes, targeted analysis provides only part of the overall picture.<h4>The Fluorine Mass Balance Problem</h4>One of the most important concepts discussed in the interview is fluorine mass balance.When PFAS degrade, fluorinated fragments may remain in the environment.This creates a critical question:Are treatment technologies truly destroying PFAS, or merely transforming them into shorter-chain PFAS compounds?To answer this, researchers perform fluorine mass balance calculations using:<ul><li>Targeted PFAS analysis</li><li>Fluoride measurements</li><li>Total organic fluorine measurements</li></ul>A successful destruction process should ultimately convert PFAS into fluoride ions rather than simply producing smaller PFAS molecules.<h4>Advanced Analysis, Treatment Technologies, and Future Directions</h4><h5>Combining Targeted and Bulk Fluorine Measurements</h5>Dr. Terry's group complements targeted LC-MS analysis with measurements of total organic fluorine.Approaches include:<ul><li>Absorbable Organic Fluorine (AOF)</li><li>Extractable Organic Fluorine (EOF)</li><li>Combustion Ion Chromatography (CIC)</li></ul>In these methods:<ul><li>Organic fluorine is captured</li><li>Samples are combusted</li><li>Released fluoride is quantified</li></ul>This provides insight into total fluorinated content, although contributions may originate from sources beyond PFAS, including pharmaceuticals and consumer products.<h4>Surprising Findings from Combined Analysis</h4>One important finding from wastewater studies was that targeted PFAS measurements accounted for only a small fraction of total organic fluorine.Dr. Terry reports that:<ul><li>Approximately 4% of measured AOF could be explained by targeted PFAS compounds</li><li>The majority of organic fluorine remained unidentified</li></ul>This suggests that environmental fluorine chemistry is considerably more complex than currently represented by routine monitoring programs.<h4>Preventing PFAS Contamination in the Laboratory</h4>PFAS analysis requires exceptionally strict quality control.Dr. Terry's laboratory routinely:<ul><li>Tests every new batch of SPE cartridges</li><li>Tests carbon tubes before use</li><li>Uses DI water blanks</li><li>Verifies consumables labeled as PFAS-free</li><li>Collects field blanks</li><li>Monitors analytical blanks throughout workflows</li></ul>These practices help prevent contamination from laboratory materials and consumables, a common challenge in ultra-trace PFAS analysis.<h4>Current PFAS Treatment Technologies</h4>Three technologies currently dominate PFAS removal in drinking water treatment:<ul><li>Granular Activated Carbon (GAC)</li><li>Ion Exchange Resins</li><li>Reverse Osmosis (RO)</li></ul>Selection depends on:<ul><li>PFAS concentration</li><li>Water quality</li><li>Local operating conditions</li><li>Utility infrastructure</li></ul>Although many emerging technologies are being investigated, these remain the most widely implemented solutions.<h4>Membrane Filtration and Pretreatment</h4>Dr. Terry collaborates with colleagues studying membrane-based PFAS treatment.Her own work focuses on pretreatment through biological filtration.The strategy involves:<ul><li>Removing natural organic matter</li><li>Reducing membrane fouling</li><li>Improving membrane performance</li><li>Extending operational efficiency</li></ul>This integrated approach demonstrates how multiple treatment technologies can work together to improve PFAS removal.<h4>Regional Monitoring Projects</h4>The University of Alabama team participates in EPA-supported monitoring efforts along the Gulf Coast.Their observations indicate:<ul><li>PFAS rarely occur alone</li><li>Multiple PFAS compounds frequently co-occur</li><li>Contamination often originates from identifiable point sources</li></ul>Examples include:<ul><li>Industrial facilities</li><li>Manufacturing operations</li><li>Military installations</li><li>Carpet manufacturing facilities</li></ul>Source identification remains a critical component of environmental monitoring programs.<h4>Future Directions for PFAS Monitoring</h4>Looking ahead, Dr. Terry sees several opportunities for improvement.Desired advances include:<ul><li>In situ monitoring technologies</li><li>Portable detection systems</li><li>Reduced analytical complexity</li><li>Lower instrument costs</li><li>Less expensive consumables</li><li>Faster analysis workflows</li></ul>Current PFAS testing requires substantial expertise, specialized instrumentation, and rigorous quality control, making widespread implementation challenging.<h4>Dr. Terry's Perspective on Long-Term Solutions</h4>When asked what major PFAS challenge she would most like to solve, Dr. Terry offered a broader perspective.Rather than focusing solely on remediation, she emphasized prevention.Her view is that society should:<ul><li>Better evaluate chemical toxicity before commercialization</li><li>Assess risks before large-scale deployment</li><li>Reduce introduction of harmful compounds into the environment</li><li>Support utilities tasked with contaminant removal</li></ul>She notes that water utilities often bear the responsibility of removing contaminants they did not create, highlighting the need for broader societal and regulatory support.<h4>Final Thoughts</h4>Dr. Terry encourages consumers to:<ul><li>Learn where their drinking water originates</li><li>Read annual water quality reports</li><li>Stay informed about local water quality</li><li>Consider appropriate home filtration where needed</li></ul>At the same time, she emphasizes confidence in municipal water systems and the importance of continued investment in water quality research, monitoring, and treatment technologies.<h4>Conclusion</h4>PFAS remain one of the most complex challenges in environmental chemistry and water treatment. Through advanced analytical methods such as LC-MS/MS, combustion ion chromatography, fluorine mass balance approaches, and large-scale monitoring programs, researchers like Dr. Leigh Terry are helping improve our understanding of these persistent contaminants.The interview highlights that solving the PFAS challenge will require a combination of better analytical tools, improved treatment technologies, stronger regulatory frameworks, and a greater emphasis on prevention before contaminants enter the environment.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

PFAS in Water: Why We’re Missing 96% of the Problem

Article

Product

Video

Scientists

Environment

Water

Interview

Science and research

Software

Since 1991 DataApex develops and manufactures chromatography data stations. DataApex is constantly striving to provide users with efficient and up-to-date tools for chromatography data processing.

DataApex

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Agilent Technologies

SelectScience

Reversed phase is the most common mode of HPLC but if it’s not working for you, don’t despair, there are other options. Perhaps HILIC, Chiral, IEX, GPC/SEC, Affinity, SFC, or HIC might be better suited to your sample type.
In this seminar, we will look at additional chromatographic techniques and discuss:
<ul>
<li>Mechanism of separation
</li>
<li>Column selection and available chemistries
</li>
<li>Typical method and eluent conditions
</li>
</ul>
Becoming familiar with other modes of chromatography and investigating alternative chemistry options can result in an improved separation or provide additional information for your sample.
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: There is More to HPLC Than Reversed Phase; Exploring Other Options

There is More to HPLC Than Reversed Phase; Exploring Other Options

There is More to HPLC: Exploring Other Options

Selecting the best GPC solution – column, solvent, calibration standards, detector, etc. – can be difficult.
This presentation will cover the common questions that should be asked and aspects that should be considered when developing a GPC method so that it is robust and reproducible.
Topics that will be covered include:
<ul>
<li>Solvent choice – importance of selection
</li>
<li>Polymer Standards – choosing correctly
</li>
<li>Column choice – organic or aqueous, key selection criteria
</li>
<li>Combining columns of different types – it is NOT always a good idea
</li>
<li>Detectors – appropriate for my sample and calibration standards
</li>
</ul>
Taking time to address each of these specific areas can help you to achieve long term, reproducible, and reliable GPC results. Relevant application examples will be given.
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: GPC: Practical Steps in GPC Method Development

GPC: Practical Steps in GPC Method Development

Common questions that should be asked and aspects that should be considered when developing a GPC method so that it is robust and reproducible.

You’re required to separate your sample by “Size in Solution”. There are several terms used to describe the chromatographic process of separating molecules according to size but which is the correct one for your sample.
In this presentation we will:
Clarify the terms
Compare both their similarities and differences
Look at sample types, polymer vs. biomolecule and why the choice of column IS important
Discuss method development considerations like mobile phase and calibration curves
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: Clearing Up the Confusion - GPC/SEC/GFC - What, When, Why and How

Clearing Up the Confusion - GPC/SEC/GFC - What, When, Why and How

There are several terms used to describe the chromatographic process of separating molecules according to size but which is the correct one for your sample.

Clearing Up the Confusion- GPC/SEC/GFC- What, When, Why, How

GPC/SEC is a non-interactive chromatographic technique that will separate samples based on their size in solution and NOT on their chemistry. How do you choose, e.g. the right mobile phase, column, etc. for your sample?
In this webinar, we will examine the following elements of GPC/SEC method development:
<ul>
<li>Sample type – Polymer vs Protein
</li>
<li>Solvent choice – Organic vs Aqueous
</li>
<li>Columns – Traditional, NEW Multisolvent column (for both GPC &amp; SEC), Fast GPC; Which is best and how can you maximize column performance thru selection
</li>
<li>Calibration – What standards are appropriate to use; Why and why not
</li>
<li>Detection – RI and Advanced Detection We will look at each of these areas, provide application examples, and valuable tips to help you develop a GPC/SEC method that is both robust and reproducible.
</li>
</ul>
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: Encore Performance!!! GPC/SEC Method Development; It’s Not Just About Sample Size in Solution

Encore Performance!!! GPC/SEC Method Development; It’s Not Just About Sample Size in Solution

GPC/SEC Method Development

A short review of GPC/SEC theory and technique including conventional and multiple detection analysis is followed by a look at current applications of GPC/SEC in the fields of Biotechnology and Biopharmaceuticals research and manufacturing.
GPC/SEC has traditionally been applied in synthetic polymer production and related product manufacturing. It has also been widely used in analysis of natural products. GPC/SEC provides valuable characterization by molecular size, molecular weight and molecular weight distribution. It is now being increasing applied to discovery, production and manufacturing of materials for Biotechnology and Biopharmaceuticals in drug deliveries, therapeutic products and medical devices. Attendees will benefit from review of technique and applications information.
<blockquote>
Presenter: Richard J. Lentner (Field Applications Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Richard J. Lentner is a Field Applications Engineer with Agilent Technologies supporting the broad portfolio of Agilent products for GPC including hardware systems, specialty systems (HTGPC, Triple Detection GPC) Software (GPC/SEC, Multi Detection GPC, BIO-SEC), GPC consumable GPC Columns and Standards. He delivers training and consulting within America Field Operations with over thirty years in GPC support, sales and service of GPC related products. His studies include Biology, Chemistry and Biochemistry.
</blockquote>

Agilent Technologies: Applications in Gel Permeation/Size Exclusion Chromatography (GPC/SEC) for the Biotechnology and Biopharmaceutic

Applications in Gel Permeation/Size Exclusion Chromatography (GPC/SEC) for the Biotechnology and Biopharmaceutic

GPC/SEC theory and technique including conventional and multiple detection analysis.

Applications in Gel Permeation/Size Exclusion Chromatography

In most HPLC separations there is a wanted interaction of the sample with a chromatography packing.
When doing GPC/SEC separations, that is not the case. GPC/SEC is a noninteractive technique that separates samples based on their size in solution and not on their chemistry. This presentation will cover the common questions that should be asked when developing a robust and reproducible GPC/SEC method.
Topics will include:
<ul>
<li>Sample type: protein vs polymer
</li>
<li>Solvent Selection and its importance
</li>
<li>Column Choices &amp; how to choose correctly
</li>
<li>Calibrants
</li>
<li>Detector &amp; Instrument Considerations
</li>
</ul>
As we discuss each topic area we’ll look at examples and provide valuable tips that can help you achieve long term reproducible and reliable results.
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: From Proteins to Polymers – GPC-SEC: Understanding Column Selection and Method Considerations for Your Sample

From Proteins to Polymers – GPC-SEC: Understanding Column Selection and Method Considerations for Your Sample

Common questions that should be asked when developing a robust and reproducible GPC/SEC method.

Understanding Column Selection and Method Considerations

GPC/SEC, Gel Permeation Chromatography or Size Exclusion Chromatography, is a non-interactive chromatographic technique that separates analytes based on their size in solution.
It is often used in laboratories for determination of a polymers&#39; molecular weight distribution but has many other uses.
In this talk we will:
<ul>
<li>Review GPC theory
</li>
<li>Discuss why molecular weight distribution is important
</li>
<li>Look at the different types of columns and their uses
</li>
<li>Cover key column selection criteria
</li>
<li>Show how key parameters like concentration, particle size, and injection volume can affect your separation
</li>
</ul>
We will also look at examples of common mistakes and pitfalls relating to solvent choice, calibration standards, and combining columns in series.
<blockquote>
Presenter: Jean Lane (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Jean has been employed with Agilent since Nov 2010 in technical and applications support and has a primary role supporting Agilent’s full line of LC columns and consumables, which also includes support for Agilent’s GPC/SEC product line. She came to Agilent thru acquisition of Varian and the former Polymer Laboratories. Jean has 20 plus years of technical and applications support for both HPLC and GPC consumable products. In addition to practical chromatography experience in the laboratory, she has had many, many years in her technical role involving customer support providing assistance and troubleshooting for customer chromatography issues.
</blockquote>

Agilent Technologies: Gel Permeation Chromatography Basics and Beyond

Gel Permeation Chromatography Basics and Beyond

GPC/SEC, Gel Permeation Chromatography or Size Exclusion Chromatography.

The technique of Gel Permeation Chromatography is conceptually simple: It is a separation based on size where no enthalpic interactions are observed.
In practice, GPC is often much more involved yielding involved method development and data that can be difficult to interpret. Though GPC can seem mystifying at times 90% of the success is achieved by using the proper columns for your application.
During this e-seminar we will discuss what is new in GPC column technology, different types of stationary phases, and how to choose the best columns which yield:
<ul>
<li>Improved resolution
</li>
<li>Improved reproducibility
</li>
<li>Improved accuracy
</li>
<li>Improved analysis time
</li>
</ul>
The goal of the e-seminar is to illustrate how proper GPC column selection can make the difference between good and great chromatography.
<blockquote>
Presenter: Michael Kruger (Application Engineer, Agilent Technologies, Inc.)
</blockquote>

Agilent Technologies: Achieving Superior GPC Results Through the Correct Column Selection

Achieving Superior GPC Results Through the Correct Column Selection

What is new in GPC column technology, different types of stationary phases, and how to choose the best columns.

Achieving Superior GPC Results - Correct Column Selection

Multi-Angle Light Scattering (MALS) has become the standard technique to determine molecular weight (MW) and size (radius of gyration) of macromolecules. A new MALS detector provides extraordinary sensitivity for GPC, HPLC, and UHPLC. It integrates the best of both Multi-Angle and Low-Angle Light Scattering concepts to create a new paradigm in light scattering detection. Its enhanced capabilities and unprecedented sensitivity provide a direct and accurate measurement of molecular weight.
In this webinar you will learn how MALS detection can deliver valuable information for the characterization of macromolecule swith a focus on biomolecules such as antibodies or oligonucleotides.
<h3>Learning Objectives</h3>
<ul>
<li>Learn about the fundamentals of light scattering detection.</li>
<li>Understand the latest approaches used to analyse macromolecules by light scattering.</li>
<li>Discover the benefits of MALS detection for the analysis of biomolecules.</li>
</ul>
<blockquote>
Presenter: Patrick Endres (Senior Laboratory Specialist, Tosoh Bioscience GmbH)
</blockquote>
<blockquote>
Patrick holds a M.Sc. degree in bio engineering from the Karlsruhe Institute of Technology. He joined Tosoh Bioscience in 2016 and is currently responsible for the application development and benchmarking of Tosoh Bioscience’s process resins, HPLC and UHPLC columns, as well as detectors. He authored multiple application notes and scientific papers and presents his work to scientist and customers and at conferences.
</blockquote>

Pixabay/HeungSoon: LenS3 – MALS Technology for Next Generation Biopharmaceuticals

LenS3 – MALS Technology for Next Generation Biopharmaceuticals

Recombinant adeno-associated viral (rAAV) vectors have emerged as the leading gene delivery platform for gene therapy and genetic vaccination. For this promising gene delivery vector to fully realize its therapeutic or prophylactic potential, a rational design strategy is desired. The current challenges in viral vector manufacturing robustness, scale up, and productivity will need to be addressed to turn this mode of treatment into an accessible global benefit. To meet this goal, reliable analytical technologies to help establish a structure-function relationship, guide the development of manufacturing processes, and assess the quality of clinical materials have become increasingly relevant and urgent.
In this upcoming webinar, hear from Ximo Zhang, senior scientist at Waters, to discover the challenges associated with analyzing AAV samples, and discover how LC and LC-MS workflows can help solve these setbacks, including those that employ size-exclusion chromatography (SEC), anion-exchange chromatography (AEX), protein reversed phase LC-MS, and peptide mapping LC-MS based analyses.
<h3>Watch this webinar to learn</h3>
<ul>
<li>How to use SEC for AAV aggregation and titer analysis</li>
<li>Optimize IEX for AAV empty/full capsids analysis</li>
<li>Develop LC/MS-based method for AAV proteins and peptides analysis</li>
</ul>
<h3>Who should attend?</h3>
This webinar will provide insights for researchers interested in LC and LC-MS methods for gene therapy or nucleic acid-based vaccine products within these organizations:
<ul>
<li>Pharmaceutical</li>
<li>Contract research organizations</li>
<li>Academia</li>
<li>Government laboratories</li>
<li>Analytical scientists analyzing AAV or related biomolecules</li>
<li>Laboratory managers and directors responsible for advancing development and manufacture AAV-based modalities</li>
</ul>
<blockquote>
Presenter: Ximo Zhang (senior scientist at Waters)
</blockquote>
<blockquote>
 Ximo Zhang is a Senior Scientist in the Biopharma scientific group at Waters. Ximo graduated from Purdue University with a Ph.D. in Analytical Chemistry from Professor Mary Wirth’s group in 2016. After graduation, Ximo joined Waters to continue her pursuit in contributing to the advancement in separation science. In the past few years, Ximo has developed a series of novel LC and LC-MS based methods and workflows for the analysis of biopharmaceuticals, including methodologies for released glycans, fusion proteins, synthetic peptides, and oligonucleotides. Ximo’s research currently focuses on the analysis of adeno-associated virus using LC and MS technologies.
</blockquote>
<blockquote>
Presenter: Stephan M. Koza, PhD (Principal Scientist, Waters Corporation)
</blockquote>
<blockquote>
Stephan has worked for Waters for 9 years and leads an applications group at Waters that has a primary focus on the use of UPLC, HPLC, LC-MS, and sample preparation chemistries and columns for the analysis of biomolecules. Prior to joining Waters he had nearly twenty years of experience with biopharmaceutical characterization and analytical method development.
</blockquote>

Pixabay/Thiago Lazarino: Taming the Viral Beast: Applying LC and LC-MS Technologies to the Analysis of rAAV Viral Vectors

LCMS webinars focusing on GPC/SEC - page 21

Taming the Viral Beast: Applying LC and LC-MS Technologies to the Analysis of rAAV Viral Vectors